Search

Your search keyword '"Aspinall, Richard"' showing total 770 results
Start Over Author "Aspinall, Richard"
770 results on '"Aspinall, Richard"'

1. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.

Author

Hirschfield, Gideon M, Shiffman, Mitchell L, Gulamhusein, Aliya, Kowdley, Kris V, Vierling, John M, Levy, Cynthia, Kremer, Andreas E, Zigmond, Ehud, Andreone, Pietro, Gordon, Stuart C, Bowlus, Christopher L, Lawitz, Eric J, Aspinall, Richard J, Pratt, Daniel S, Raikhelson, Karina, Gonzalez-Huezo, Maria S, Heneghan, Michael A, Jeong, Sook-Hyang, Ladrón de Guevara, Alma L, Mayo, Marlyn J, Dalekos, George N, Drenth, Joost PH, Janczewska, Ewa, Leggett, Barbara A, Nevens, Frederik, Vargas, Victor, Zuckerman, Eli, Corpechot, Christophe, Fassio, Eduardo, Hinrichsen, Holger, Invernizzi, Pietro, Trivedi, Palak J, Forman, Lisa, Jones, David EJ, Ryder, Stephen D, Swain, Mark G, Steinberg, Alexandra, Boudes, Pol F, Choi, Yun-Jung, McWherter, Charles A, and ENHANCE Study Group*

Subjects
ENHANCE Study Group*, Humans, Liver Cirrhosis, Biliary, Pruritus, Acetates, Ursodeoxycholic Acid, Alkaline Phosphatase, Cholagogues and Choleretics, Digestive Diseases, Liver Disease, Rare Diseases, Clinical Trials and Supportive Activities, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Medical Biochemistry and Metabolomics, Clinical Sciences, Immunology, Gastroenterology & Hepatology
Abstract

Background and aimsENHANCE was a phase 3 study that evaluated efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor-δ (PPAR) agonist, versus placebo in patients with primary biliary cholangitis with inadequate response or intolerance to ursodeoxycholic acid (UDCA).Approach and resultsPatients were randomized 1:1:1 to oral seladelpar 5 mg (n=89), 10 mg (n=89), placebo (n=87) daily (with UDCA, as appropriate). Primary end point was a composite biochemical response [alkaline phosphatase (ALP) < 1.67×upper limit of normal (ULN), ≥15% ALP decrease from baseline, and total bilirubin ≤ ULN] at month 12. Key secondary end points were ALP normalization at month 12 and change in pruritus numerical rating scale (NRS) at month 6 in patients with baseline score ≥4. Aminotransferases were assessed. ENHANCE was terminated early following an erroneous safety signal in a concurrent, NASH trial. While blinded, primary and secondary efficacy end points were amended to month 3. Significantly more patients receiving seladelpar met the primary end point (seladelpar 5 mg: 57.1%, 10 mg: 78.2%) versus placebo (12.5%) ( p < 0.0001). ALP normalization occurred in 5.4% ( p =0.08) and 27.3% ( p < 0.0001) of patients receiving 5 and 10 mg seladelpar, respectively, versus 0% receiving placebo. Seladelpar 10 mg significantly reduced mean pruritus NRS versus placebo [10 mg: -3.14 ( p =0.02); placebo: -1.55]. Alanine aminotransferase decreased significantly with seladelpar versus placebo [5 mg: 23.4% ( p =0.0008); 10 mg: 16.7% ( p =0.03); placebo: 4%]. There were no serious treatment-related adverse events.ConclusionsPatients with primary biliary cholangitis (PBC) with inadequate response or intolerance to UDCA who were treated with seladelpar 10 mg had significant improvements in liver biochemistry and pruritus. Seladelpar appeared safe and well tolerated.

Published
2023

2. Critical shortfalls in the management of PBC: Results of a UK-wide, population-based evaluation of care delivery

Author

Abbas, Nadir, Smith, Rachel, Flack, Steven, Bains, Vikram, Aspinall, Richard J., Jones, Rebecca L., Burke, Laura, Thorburn, Douglas, Heneghan, Michael, Yeoman, Andrew, Leithead, Joanna, Braniff, Conor, Robertson, Andrew, Mitchell, Chris, Thain, Collette, Mitchell-Thain, Robert, Jones, David, Trivedi, Palak J., Mells, George F., and Alrubaiy, Laith

Published
2024
Full Text
View/download PDF

3. UK-Wide Multicenter Evaluation of Second-line Therapies in Primary Biliary Cholangitis

Author

Abbas, Nadir, Culver, Emma L., Thorburn, Douglas, Halliday, Neil, Crothers, Hannah, Dyson, Jessica K., Phaw, April, Aspinall, Richard, Khakoo, Salim I., Kallis, Yiannis, Smith, Belinda, Patanwala, Imran, McCune, Anne, Chimakurthi, Chenchu R., Hegade, Vinod, Orrell, Michael, Jones, Rebecca, Mells, George, Thain, Colette, Thain, Robert-Mitchell, Jones, David, Hirschfield, Gideon, and Trivedi, Palak J.

Published
2023
Full Text
View/download PDF

6. Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group

Author

McPherson, Stuart, Armstrong, Matthew J, Cobbold, Jeremy F, Corless, Lynsey, Anstee, Quentin M, Aspinall, Richard J, Barclay, Stephen T, Brennan, Paul N, Cacciottolo, Tessa M, Goldin, Robert D, Hallsworth, Kate, Hebditch, Vanessa, Jack, Kathryn, Jarvis, Helen, Johnson, Jill, Li, Wenhao, Mansour, Dina, McCallum, Mary, Mukhopadhya, Ashis, Parker, Richard, Ross, Valerie, Rowe, Ian A, Srivastava, Ankur, Thiagarajan, Prarthana, Thompson, Alexandra I, Tomlinson, Jeremy, Tsochatzis, Emmanuel A, Yeoman, Andrew, and Alazawi, William

Published
2022
Full Text
View/download PDF

8. Interleukin-7 and Immunorejuvenation

Author

Aspinall, Richard, Mitchell, Wayne, Lang, Pierre Olivier, Fulop, Tamas, Section editor, Fulop, Tamas, editor, Franceschi, Claudio, editor, Hirokawa, Katsuiku, editor, and Pawelec, Graham, editor

Published
2019
Full Text
View/download PDF

9. Quality standards for the management of alcohol-related liver disease: consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology ARLD special interest group

Author

Parker, Richard, primary, Allison, Michael, additional, Anderson, Seonaid, additional, Aspinall, Richard, additional, Bardell, Sara, additional, Bains, Vikram, additional, Buchanan, Ryan, additional, Corless, Lynsey, additional, Davidson, Ian, additional, Dundas, Pauline, additional, Fernandez, Jeff, additional, Forrest, Ewan, additional, Forster, Erica, additional, Freshwater, Dennis, additional, Gailer, Ruth, additional, Goldin, Robert, additional, Hebditch, Vanessa, additional, Hood, Steve, additional, Jones, Arron, additional, Lavers, Victoria, additional, Lindsay, Deborah, additional, Maurice, James, additional, McDonagh, Joanne, additional, Morgan, Sarah, additional, Nurun, Tania, additional, Oldroyd, Christopher, additional, Oxley, Elizabeth, additional, Pannifex, Sally, additional, Parsons, Graham, additional, Phillips, Thomas, additional, Rainford, Nicole, additional, Rajoriya, Neil, additional, Richardson, Paul, additional, Ryan, J, additional, Sayer, Joanne, additional, Smith, Mandy, additional, Srivastava, Ankur, additional, Stennett, Emma, additional, Towey, Jennifer, additional, Vaziri, Roya, additional, Webzell, Ian, additional, Wellstead, Andrew, additional, Dhanda, Ashwin, additional, and Masson, Steven, additional

Published
2023
Full Text
View/download PDF

10. Critical shortfalls in the management of PBC: results of a UK-wide, population-based evaluation of care delivery

Author

Abbas, Nadir, primary, Smith, Rachel, additional, Flack, Steven, additional, Bains, Vikram, additional, Aspinall, Richard J., additional, Jones, Rebecca L., additional, Burke, Laura, additional, Thorburn, Douglas, additional, Heneghan, Michael, additional, Yeoman, Andrew, additional, Leithead, Joanna, additional, Braniff, Conor, additional, Robertson, Andrew, additional, Mitchell, Chris, additional, Thain, Collette, additional, Mitchell-Thain, Robert, additional, Jones, David, additional, Trivedi, Palak J., additional, Mells, George F., additional, Alrubaiy, Laith, additional, Jones, Rebecca, additional, Mells, George, additional, Trivedi, Palak, additional, Flack, Steve, additional, Abbas, Nadir, additional, Abdelsalam, Basma Ahmed, additional, Abdul, Samad, additional, Abduljabbar, Duaa, additional, Abusrewil, Anwar, additional, Adams, Lauren, additional, Adam, Mohamed, additional, Ahmed, Salman, additional, Ali, Jawad, additional, Aldridge, Robin, additional, Al Imran, Tanzil, additional, Alleyne, Lance, additional, Al-Shakhshir, Sarah, additional, Al-Talib, Ismaeel, additional, Amin, Muhammad Nauman, additional, Anand, Tanmay, additional, Arms-Williams, Bradley, additional, Ashraf, Fahad, additional, Ashraf, Muteeb, additional, Aslam, Usama, additional, Asmat, Huma, additional, Aung, Zaw Myo, additional, Au-Yeung, Desson, additional, Aydogan, Rosewan, additional, Babar, Nauman, additional, Baig, Faisal, additional, Bamidele, Opeyemi, additional, Banerjee, Arindam, additional, Baqai, M Fahd, additional, Barakat, Ezzeldin, additional, Barcan, Alina, additional, Bennett, Kris, additional, Bhandal, Mandeep Kaur, additional, Bhushan, Azad, additional, Bonello, Karl, additional, Bordom, Daniel, additional, Bower, Joshua, additional, Bray, Gary, additional, Brennan, Paul, additional, Brown, Rebecca, additional, Brunchi, Andrei, additional, Burns, Karen, additional, Campbell, Iona, additional, Campbell, Roisin, additional, Caracostea, Andra, additional, Carbonell, M., additional, Cargill, Zillah, additional, Cathcart, Jennifer, additional, Chahal, Manpreet, additional, Chakrabarty, Gayatri, additional, Cheung, Michelle, additional, Chikhlia, Anmol, additional, Choon, Xin Yi, additional, Chung, Yooyun, additional, Clancy, Jennifer, additional, Coleman, Emma, additional, Cooper, Christopher, additional, Cox, Zoe, additional, Coyle, Jo, additional, Crocombe, Dominic, additional, Crombie, Joanna, additional, Cumlat, Lourdes, additional, Davies, Courtney, additional, Dearden, Janet, additional, Delaney, Mollie, additional, Dickson, Bruce, additional, Dolman, Grace, additional, Donnelly, Hannah, additional, Dunn, Rebecca, additional, Eales, Louise, additional, Easaw, Jonathan, additional, El Gindy, Mostafa, additional, Ellwood, Kathy, additional, Elsaie, Maged, additional, El-Sayed, Ahmed, additional, Evans, Louise, additional, Farrow, Samantha, additional, Fellows, Helen, additional, Foxton, Matthew, additional, George, Keith, additional, Gerges, Andrew, additional, Giles, Ben, additional, Gomez, David, additional, Goodman, Stephanie, additional, Gopaul, Akshaye, additional, Gormley, Sarah, additional, Gouda, Mahmoud, additional, Gupta-Kaistha, Aarav, additional, Guthrie, Sarah, additional, Hackett, Richard, additional, Hadjinicolaou, Andreas, additional, Halliday, Neil, additional, Hamzah, Basem, additional, Haq, Bisam-ul, additional, Hassall, James, additional, Herman, Omar, additional, Hewitt, Mathew, additional, Hicks, Amy, additional, Hill, Lorraine, additional, Hlaing, Htar Htar, additional, Howard, Anna, additional, Hsu, Catherine, additional, Iqbal, Muhammad Javaid, additional, Isibor, Jumi, additional, Ismail, Asem, additional, Jamal, Jamal W., additional, James, Joel, additional, Javid, Pernia, additional, Javed, Nasir, additional, Jeyanesan, Dhaarica, additional, Jones, Rhiannon, additional, Jopson, Laura, additional, Aleem, M. Junaid, additional, Kallis, Yiannis, additional, Kanwar, Sophia, additional, Karim, Syed, additional, Kelly, Christopher, additional, Khalid, Muhammad Usman, additional, Khan, Asif, additional, Khani, Aria, additional, Kim, Yun, additional, King, Jade, additional, Kirby, Meera, additional, Koo, Sara, additional, Kovammal, Shemin, additional, Kronsten, Victoria, additional, Lagundoye, Ayo, additional, Lam, Jonathan, additional, Lam, Wai Liam, additional, Layard, Brooke, additional, Liaros, Angela, additional, Linn, Thinzar, additional, Lofthouse, Megan, additional, Lynch, Ruairi, additional, Madayala, Mohan, additional, Mahalingam, Aarani, additional, Mahgoub, Moawad, additional, Manan, Abdul, additional, Martin, Vanessa, additional, Masterman, Ben, additional, Matthews, Charmaine, additional, Martini, Iana, additional, Maxan, Maria-Emanuela, additional, McCallion, Nicola, additional, McCormack, Matthew, additional, McDermott, Sarah, additional, McDowell, Hannah, additional, McHugh, Kate, additional, Michail, Stephanie, additional, Mistry, Neil, additional, Mohandas, Dhanoop, additional, Mole, Sean, additional, Moore-Gillon, Claudia, additional, Morgan, James, additional, Morris, Sean, additional, Murray, Jennifer, additional, Murthy, Sruthi, additional, Nasiri, Ruhullah, additional, Nasim, Muhammad Ahsan, additional, Nathwani, Rooshi, additional, Nicholson, Edward, additional, Nigam, Gaurav, additional, Nomani, Murtaza, additional, Nixon, Kirsty, additional, Ogle, Laura, additional, Okeke, Olaku, additional, Olabintan, Olaolu, additional, Ming San, Elaine Ong, additional, Orpen-Palmer, Josh, additional, Orrell, Michael, additional, Osuoha, Glenda, additional, Owen, Christina, additional, Pandya, Aashish, additional, Papamargaritis, Ioannis, additional, Parker, Maurizio, additional, Perera, Suvey, additional, Perry, Alex, additional, Perry, Robert, additional, Peters, Rory, additional, Phaw, Naw April, additional, Phillips, Abimbola, additional, Phoolchund, Anju, additional, Pillay, Lushen, additional, Platten, Emily, additional, Pohl, Keith, additional, Possamai, Lucia, additional, Praman, Krithivasan, additional, Prasad, Yash, additional, Punton, Andrew, additional, Rahimi, Abdul Hameed, additional, Ramful, Satyasheel, additional, Ratcliff, Naomi, additional, Rehman, Zaira, additional, Riggott, Christy, additional, Robinson, Emma, additional, Rushbrook, Simon, additional, Salih, Nafisa, additional, Samuel, David, additional, Saunsbury, Emma, additional, Scott, Jenny, additional, Shah, Jayshri, additional, Shearer, Jessica, additional, Sheth, Abhishek, additional, Sidhu, Harsimranjit, additional, Silcock, Abigail, additional, Sinclair, Sophie, additional, Singh, Prabhsimran, additional, Sinha, Rohit, additional, Smith, Belinda, additional, Sood, R., additional, Spyridou, Chrysoula, additional, Steen, Jennifer, additional, Stephen, Kate, additional, Stevenson, Jason, additional, Sumanariu, Elena, additional, Summers, Nikki, additional, Sweeney, Liz, additional, Tan, Huey, additional, Taylor, Olivia, additional, Tham, Jennifer, additional, Thatcher, Amy, additional, Jones, Helen Thompson, additional, Tufail, Qamar, additional, Udayachandran, Varun, additional, Vakeeswarasarma, Vithushan, additional, Parambil, Jessiya Veliyankodan, additional, Vithayathil, Mathew, additional, Volcek, Edvard, additional, Vyas, Anand, additional, Waddell, Katy, additional, Webb, Gwilym, additional, Westlake, Emily, additional, Wetten, Aaron, additional, White, Helen, additional, Willsmore, James, additional, Wooding, Jenna, additional, Wye, John, additional, Yeoh, Irvin, additional, Zahedi, Faisal, additional, Zaman, Shakir, additional, Zotescu, Andreea, additional, and Zulfikar, Seema, additional

Published
2023
Full Text
View/download PDF

15. Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.

Author

Mayo, Marlyn J., Vierling, John M., Bowlus, Christopher L., Levy, Cynthia, Hirschfield, Gideon M., Neff, Guy W., Galambos, Michael R., Gordon, Stuart C., Borg, Brian B., Harrison, Stephen A., Thuluvath, Paul J., Goel, Aparna, Shiffman, Mitchell L., Swain, Mark G., Jones, David E. J., Trivedi, Palak, Kremer, Andreas E., Aspinall, Richard J., Sheridan, David A., and Dörffel, Yvonne

Subjects
CHOLANGITIS, CLINICAL trials, ADVERSE health care events, NON-alcoholic fatty liver disease, BIOMARKERS
Abstract

Summary: Background: Seladelpar is a potent and selective peroxisome proliferator‐activated receptor‐δ agonist that targets multiple cell types involved in primary biliary cholangitis (PBC), leading to anti‐cholestatic, anti‐inflammatory and anti‐pruritic effects. Aims: To evaluate the long‐term safety and efficacy of seladelpar in patients with PBC. Methods: In an open‐label, international, long‐term extension study, patients with PBC completing seladelpar lead‐in studies continued treatment. Seladelpar was taken orally once daily at doses of 5 or 10 mg with dose adjustment permitted for safety or tolerability. The primary analysis was for safety and the secondary efficacy analysis examined biochemical markers of cholestasis and liver injury. The study was terminated early due to the unexpected histological findings in a concurrent study for non‐alcoholic steatohepatitis, which were subsequently found to predate treatment. Safety and efficacy data were analysed through 2 years. Results: There were no serious treatment‐related adverse events observed among 106 patients treated with seladelpar for up to 2 years. There were four discontinuations for safety, one possibly related to seladelpar. Among 53 patients who completed 2 years of seladelpar, response rates increased from years 1 to 2 for the composite endpoint (alkaline phosphatase [ALP] <1.67 × ULN, ≥15% decrease in ALP, and total bilirubin ≤ULN) and ALP normalisation from 66% to 79% and from 26% to 42%, respectively. In those with elevated bilirubin at baseline, 43% achieved normalisation at year 2. Conclusions: Seladelpar was safe, and markedly improved biochemical markers of cholestasis and liver injury in patients with PBC. These effects were maintained or improved throughout the second year. Clinicaltrials.gov: NCT03301506; Clinicaltrialsregister.eu: 2017‐003910‐16. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Ten facts about land systems for sustainability

Author

Meyfroidt, Patrick, De Bremond, Ariane, Ryan, Casey M., Archer, Emma, Aspinall, Richard, Chhabra, Abha, Camara, Gilberto, Corbera, Esteve, DeFries, Ruth, Díaz, Sandra, Dong, Jinwei, Ellis, Erle C., Erb, Karl-Heinz, Fisher, Janet A., Garrett, Rachael D., Golubiewski, Nancy E., Grau, H. Ricardo, Grove, J. Morgan, Haberl, Helmut, Heinimann, Andreas, Hostert, Patrick, Jobbágy, Esteban G., Kerr, Suzi, Kuemmerle, Tobias, Lambin, Eric F., Lavorel, Sandra, Lele, Sharachandra, Mertz, Ole, Messerli, Peter, Metternicht, Graciela, Munroe, Darla K., Nagendra, Harini, Nielsen, Jonas Østergaard, Ojima, Dennis S., Parker, Dawn Cassandra, Pascual, Unai, Porter, John R., Ramankutty, Navin, Reenberg, Anette, Roy Chowdhury, Rinku, Seto, Karen C., Seufert, Verena, Shibata, Hideaki, Thomson, Allison, Turner, Billie L., Urabe, Jotaro, Veldkamp, Tom, Verburg, Peter H., Zeleke, Gete, zu Ermgassen, Erasmus K. H. J., Universitat Autònoma de Barcelona. Departament de Geografia, UCL - SST/ELI/ELIC - Earth & Climate, Environmental Geography, University of Twente, and Faculty of Geo-Information Science and Earth Observation

Subjects
Conservation of Natural Resources, Multidisciplinary, land use, Agriculture, sustainability, ITC-HYBRID, social-ecological systems, SDG 17 - Partnerships for the Goals, governance, ITC-ISI-JOURNAL-ARTICLE, 320 Political science, Humans, Renewable Energy, Social Change, 550 Earth sciences & geology, Ecosystem
Abstract

Land use is central to addressing sustainability issues, including biodiversity conservation, climate change, food security, poverty alleviation, and sustainable energy. In this paper, we synthesize knowledge accumulated in land system science, the integrated study of terrestrial social-ecological systems, into 10 hard truths that have strong, general, empirical support. These facts help to explain the challenges of achieving sustainability in land use and thus also point toward solutions. The 10 facts are as follows: 1) Meanings and values of land are socially constructed and contested; 2) land systems exhibit complex behaviors with abrupt, hard-to-predict changes; 3) irreversible changes and path dependence are common features of land systems; 4) some land uses have a small footprint but very large impacts; 5) drivers and impacts of land-use change are globally interconnected and spill over to distant locations; 6) humanity lives on a used planet where all land provides benefits to societies; 7) land-use change usually entails trade-offs between different benefits-"win-wins" are thus rare; 8) land tenure and land-use claims are often unclear, overlapping, and contested; 9) the benefits and burdens from land are unequally distributed; and 10) land users have multiple, sometimes conflicting, ideas of what social and environmental justice entails. The facts have implications for governance, but do not provide fixed answers. Instead they constitute a set of core principles which can guide scientists, policy makers, and practitioners toward meeting sustainability challenges in land use., Proceedings of the National Academy of Sciences of the United States of America, 119 (7), ISSN:0027-8424, ISSN:1091-6490

Published
2022

32. Real-world evidence of long-term survival and healthcare resource use in patients with hepatic encephalopathy receiving rifaximin-α treatment: a retrospective observational extension study with long-term follow-up (IMPRESS II)

Author

Aspinall, Richard J, primary, Hudson, Mark, additional, Ryder, Stephen D, additional, Richardson, Paul, additional, Farrington, Elizabeth, additional, Wright, Mark, additional, Przemioslo, Robert T, additional, Perez, Francisco, additional, Kent, Melanie, additional, Henrar, Roland, additional, Hickey, Joe, additional, and Shawcross, Debbie L, additional

Published
2022
Full Text
View/download PDF

34. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis

Author

Williams, Roger, Aspinall, Richard, Bellis, Mark, Camps-Walsh, Ginette, Cramp, Matthew, Dhawan, Anil, Ferguson, James, Forton, Dan, Foster, Graham, Gilmore, Sir Ian, Hickman, Matthew, Hudson, Mark, Kelly, Deirdre, Langford, Andrew, Lombard, Martin, Longworth, Louise, Martin, Natasha, Moriarty, Kieran, Newsome, Philip, O'Grady, John, Pryke, Rachel, Rutter, Harry, Ryder, Stephen, Sheron, Nick, and Smith, Tom

Published
2014
Full Text
View/download PDF

38. O07 Results of the first national audit of PBC management reveal significant variation in care delivery across the UK

Author

Smith, Rachel, primary, Abbas, Nadir, additional, Flack, Steve, additional, Yeoman, Andrew, additional, Thorburn, Douglas, additional, Aspinall, Richard, additional, Jones, Rebecca, additional, Leithead, Joanna, additional, Braniff, Conor, additional, Heneghan, Michael, additional, Thain, Collette, additional, Mitchell, Chris, additional, Mitchell-Thain, Robert, additional, Jones, David, additional, Trivedi, Palak, additional, Mells, George, additional, and Al-Rubaiy, Laith, additional

Published
2022
Full Text
View/download PDF

39. A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis

Author

Bowlus, Christopher L., primary, Galambos, Michael R., additional, Aspinall, Richard J., additional, Hirschfield, Gideon M., additional, Jones, David E.J., additional, Dörffel, Yvonne, additional, Gordon, Stuart C., additional, Harrison, Stephen A., additional, Kremer, Andreas E., additional, Mayo, Marlyn J., additional, Thuluvath, Paul J., additional, Levy, Cynthia, additional, Swain, Mark G., additional, Neff, Guy W., additional, Sheridan, David A., additional, Stanca, Carmen M., additional, Berg, Christoph P., additional, Goel, Aparna, additional, Shiffman, Mitchell L., additional, Vierling, John M., additional, Boudes, Pol, additional, Steinberg, Alexandra, additional, Choi, Yun-Jung, additional, and McWherter, Charles A., additional

Published
2022
Full Text
View/download PDF

40. Association of long term methotrexate therapy with liver fibrosis markers: a multi-centre prospective case-control study

Author

Atallah, Edmond, primary, Grove, Jane, additional, Crooks, Colin, additional, Burden-teh, Esther, additional, Murphy, Ruth, additional, Moreea, Sulleman, additional, Abhishek, Abhishek, additional, Jordan, Kelsey, additional, Ala, Aftab, additional, Hutchinson, David, additional, Aspinall, Richard, additional, and Aithal, Guruprasad, additional

Published
2022
Full Text
View/download PDF

41. Critical shortfalls in the management of PBC: results of the first nationwide, population-based study of care delivery across the U.K.

Author

Abbas, Nadir, primary, Smith, Rachel, additional, Flack, Steve, additional, Aspinall, Richard, additional, Jones, Rebecca L., additional, Leithead, Joanna, additional, Thorburn, Douglas, additional, Braniff, Conor, additional, Heneghan, Michael, additional, Yeoman, Andrew, additional, Thain, Collette, additional, Mitchell, Chris, additional, Mitchell-Thain, Robert, additional, Jones, David, additional, Trivedi, Palak, additional, Mells, George, additional, and Al-Rubaiy, Laith, additional

Published
2022
Full Text
View/download PDF

49. Ecosystem Services: Nature's Balance Sheet [with Response]

Author

ASPINALL, RICHARD, GREGORY, PETER, BATEMAN, IAN J., HARWOOD, AMII R., MACE, GEORGINA M., WATSON, ROBERT T., ABSON, DAVID J., ANDREWS, BARNABY, BINNER, AMY, CROWE, ANDREW, DAY, BRETT H., DUGDALE, STEVE, FEZZI, CARLO, FODEN, JO, HADLEY, DAVID, HAINES-YOUNG, ROY, HULME, MARK, KONTOLEON, ANDREAS, LOVETT, ANDREW A., MUNDAY, PAUL, PASCUAL, UNAI, PATERSON, JAMES, PERINO, GRISCHA, SEN, ANTARA, SIRIWARDENA, GAVIN, VAN SOEST, DAAN, and TERMANSEN, METTE

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results